Try a new search

Format these results:

Searched for:

person:brunob04

in-biosketch:true

Total Results:

283


Multiomic Mapping of Copy Number and Structural Variation on Chromosome 1 (Chr1) Highlights Multiple Recurrent Disease Drivers [Meeting Abstract]

Blaney, Patrick; Boyle, Eileen M.; Wang, Yubao; Ghamlouch, Hussein; Choi, Jinyoung; Williams, Louis; James, Stoeckle; Siegel, Ariel; Razzo, Beatrice; Braunstein, Marc; Kaminetzky, David; Arbini, Arnaldo A.; Bruno, Benedetto; Corre, Jill; Montes, Lydia; Auclair, Daniel; Davies, Faith E.; Tsirigos, Aristotelis; Rustad, Even H.; Maura, Francesco; Landgren, Ola; Bauer, Michael A.; Walker, Brian; Morgan, Gareth
ISI:000736398803021
ISSN: 0006-4971
CID: 5389172

Unifying the Definition of High-Risk in Multiple Myeloma [Meeting Abstract]

Siegel, Ariel; Boyle, Eileen M.; Blaney, Patrick; Wang, Yubao; Ghamlouch, Hussein; Choi, Jinyoung; Caro, Jessica; Williams, Louis; Razzo, Beatrice; Arbini, Arnaldo A.; Braunstein, Marc; Kaminetzky, David; Auclair, Daniel; Pawlyn, Charlotte; Cairns, David; Jackson, Graham; Walker, Brian; Bruno, Benedetto; Morgan, Gareth J.; Davies, Faith E.
ISI:000736413903013
ISSN: 0006-4971
CID: 5389182

Hispanic or Latin American Ancestry Is Associated with a Similar Genomic Profile and a Trend Toward Inferior Outcomes in Newly Diagnosed Multiple Myeloma As Compared to Non-Hispanic White Patients in the Multiple Myeloma Research Foundation (MMRF) CoMMpassstudy [Meeting Abstract]

Williams, Louis; Blaney, Patrick; Boyle, Eileen M.; Ghamlouch, Hussein; Wang, Yubao; Choi, Jinyoung; Bauer, Michael A.; Siegel, Ariel; Stoeckle, James; Razzo, Beatrice; Auclair, Daniel; Kaminetzky, David; Braunstein, Marc; Bruno, Benedetto; Arbini, Arnaldo A.; Walker, Brian A.; Davies, Faith E.; Morgan, Gareth J.
ISI:000835740100118
ISSN: 0006-4971
CID: 5389192

Post-Transplant Cyclophosphamide, Abatacept, and Short Course of Tacrolimus Combination (CAST) Is Safe and Seems Highly Effective in Preventing Graft-Versus-Host Disease Following Haploidentical Peripheral Blood Stem Cell Transplantation [Meeting Abstract]

Al-Homsi, A. Samer Samer; Cirrone, Frank; Cole, Kelli; Stocker, Kelsey; Bruno, Benedetto; Suarez-Londono, J. Andres; Goldberg, Judith; Abdul-Hay, Maher
ISI:000736413908030
ISSN: 0006-4971
CID: 5515792

Biomarkers for acute and chronic graft versus host disease: state of the art

Giaccone, Luisa; Faraci, Danilo Giuseppe; Butera, Sara; Lia, Giuseppe; Di Vito, Clara; Gabrielli, Giulia; Cerrano, Marco; Mariotti, Jacopo; Dellacasa, Chiara; Felicetti, Francesco; Brignardello, Enrico; Mavilio, Domenico; Bruno, Benedetto
INTRODUCTION/BACKGROUND:Despite significant advances in treatment and prevention, graft-versus-host disease (GVHD) still represents the main cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. Thus, considerable research efforts have been made to find and validate reliable biomarkers for diagnosis, prognosis and risk stratification of GVHD. AREAS COVERED/UNASSIGNED:In this review the most recent evidences on different types of biomarkers studied for GVHD, such as genetic, plasmatic, cellular markers and those associated with microbiome, were summarized. A comprehensive search of peer-review literature was performed in PubMed including meta-analysis, preclinical and clinical trials, using the terms: cellular and plasma biomarkers, graft-versus-host disease, cytokines, and allogeneic hematopoietic stem cell transplantation. EXPERT OPINION/UNASSIGNED:In the near future, several validated biomarkers will be available to help clinicians in the diagnosis of GVHD, the identification of patients at high risk of GVHD development and in patients' stratification according to its severity. Then, immunosuppressive treatment could be tailored on each patient's real needs. However, more efforts are needed to achieve this goal. Although most of the proposed biomarkers currently lack validation with large scale clinical data, their study led to improved knowledge of the biological basis of GVHD, and ultimately to implementation of GHVD treatment.
PMID: 33297779
ISSN: 1747-4094
CID: 4727612

Response assessment to venetoclax in relapsed/refractory chronic lymphocytic leukemia by ultrasonography [Letter]

Benedetti, Edoardo; Baratè, Claudia; Bruno, Benedetto; Bramanti, Emilia; Ghia, Paolo; Scarfò, Lydia; Morganti, Riccardo; Ricchiuto, Vittorio; Galimberti, Sara
PMID: 33316660
ISSN: 1873-5835
CID: 4727532

Nilotinib in steroid-refractory cGVHD: prospective parallel evaluation of response, according to NIH criteria and exploratory response criteria (GITMO criteria)

Olivieri, A; Mancini, G; Olivieri, J; Marinelli Busilacchi, E; Cimminiello, M; Pascale, S P; Nuccorini, R; Patriarca, F; Corradini, P; Bacigalupo, A; Angelini, S; Poloni, A; Grillo, G; Onida, F; Martino, M; Di Renzo, N; Nagler, A; Mordini, N; Bruno, B; Ciceri, F; Bonifazi, F
We conducted a phase I-II study to evaluate Nilotinib (NIL) safety and pharmacokinetics in 22 SR-cGVHD patients; we also evaluated ORR by using in parallel NIH criteria and an exploratory approach, combining objective improvement (OI) without failure criteria (GITMO criteria). Results: 22 patients were enrolled. After dose escalation up to 600 mg/day, MTD was not reached. Main toxicities were asthenia, headache, nausea, pruritus, cramps, and mild anemia. Mean and median plasma concentrations of NIL (C-NIL) were 817 (SD ± 450) and 773 ng/ml. ORR at 6 months, according to 2005 and 2014 NIH and GITMO criteria were 27.8%, 22.2%, and 55.6% respectively; close correspondence has been observed for ORR, according to 2014 NIH criteria, both assessed in a conventional way and assisted by dedicated software (CROSY). At 48 months OS was 75% while FFS, according to NIH and GITMO criteria, was 30 and 25%. In conclusion the safety profile of NIL and long-term outcome makes NIL an attractive option in SR-cGVHD. Exploratory GITMO criteria could represent an alternative tool for easy response evaluation in patients with prevalent skin and lung involvement, but require validation in a larger population; CROSY software showed excellent reliability in capturing ORR according to the 2014 NIH criteria.
PMID: 32332918
ISSN: 1476-5365
CID: 4727462

Immunomodulatory and clinical effects of daratumumab in T-cell acute lymphoblastic leukaemia [Letter]

Cerrano, Marco; Castella, Barbara; Lia, Giuseppe; Olivi, Matteo; Faraci, Danilo G; Butera, Sara; Martella, Federica; Scaldaferri, Matilde; Cattel, Francesco; Boccadoro, Mario; Massaia, Massimo; Ferrero, Dario; Bruno, Benedetto; Giaccone, Luisa
PMID: 32686081
ISSN: 1365-2141
CID: 4531892

Timing of Post-Transplantation Cyclophosphamide Administration in Haploidentical Transplantation: A Comparative Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Ruggeri, Annalisa; Labopin, Myriam; Battipaglia, Giorgia; Chiusolo, Patrizia; Tischer, Johanna; Diez-Martin, Jean Luiz; Bruno, Benedetto; Castagna, Luca; Moiseev, Ivan Sergeevich; Vitek, Antonin; Rovira, Montserrat; Ciceri, Fabio; Bacigalupo, Andrea; Nagler, Arnon; Mohty, Mohamad
The timing of immunosuppressive therapy used in combination with post-transplantation cyclophosphamide (PTCY) in haploidentical hematopoietic stem cell transplant (haplo-HSCT) is not standardized. We evaluated the schedules of immunosuppression therapy after haplo-HSCT in 509 patients with acute leukemia receiving PTCY on days +3 and +4 along with tacrolimus (group 1; n = 215), with cyclosporine A (CSA) and mycophenolate mofetil (MMF) from day +5 (group 2; n = 170), or CSA + MMF from day 0 or 1 with PTCY on days +3 and +5 (group 3; n = 124). Compared with the other 2 groups, patients in group 3 were younger (median age, 46 years; P = .02) and more often received bone marrow (77%; P < .01) and a regimen containing thiotepa, fludarabine, and busulfan (84%; P< .01). At 2 years, overall survival was 44% was in group 1, 48% in group 2, and 59% in group 3 (P= .15); leukemia-free survival (LFS) was 43%, 46%, and 53% (P= .05); and refined graft-versus-host disease-free, relapse-free survival (rGRFS) was 33%, 39%, and 36% (P = .02). The incidence of grade II-IV acute GVHD was 25% in group 1, 39% in group 2, and 18% in group 3 (P< .01); incidence of chronic GVHD was 25%, 21%, and 24% (P= .50); relapse incidence was 36%, 37%, and 26% (P= .02); and nonrelapse mortality was 26%, 20%, and 21% (P= .35). On multivariate analysis, early start of immunosuppression therapy at day +1 followed by PTCY was associated with a better LFS (hazard ratio [HR], .58; P= .02) and improved rGRFS (HR, .62; P = .02). In this study, the timing of immunosuppression influenced the outcomes of haplo-HSCT with PTCY. An early start of CSA + MMF with PTCY administered on days +3 and +5 improves LFS and rGRFS.
PMID: 32645444
ISSN: 1523-6536
CID: 4600732

Impact of total body irradiation- vs chemotherapy-based myeloablative conditioning on outcomes of haploidentical hematopoietic cell transplantation for acute myelogenous leukemia

Dholaria, Bhagirathbhai; Labopin, Myriam; Angelucci, Emanuele; Ciceri, Fabio; Diez-Martin, Jose L; Bruno, Benedetto; Sica, Simona; Koc, Yener; Gülbas, Zafer; Schmid, Christoph; Blaise, Didier; Carella, Angelo Michele; Visani, Guiseppe; Savani, Bipin N; Nagler, Arnon; Mohty, Mohamad
The optimal myeloablative conditioning (MAC) for patients undergoing haploidentical hematopoietic cell transplantation (haplo-HCT) is unknown. We studied the outcomes of total body irradiation (TBI) vs chemotherapy (CT) based MAC regimens in acute myeloid leukemia (AML) patients. The study included 1008 patients who underwent first haplo-HCT with post-transplant cyclophosphamide, following TBI (N = 89, 9%) or CT (n = 919, 91%) based MAC. Patients in the TBI cohort were younger (median age, 38 vs 47 years, P < .01) and more likely to receive BM graft (57% vs 43%, P = .01). Two-year overall chronic GVHD (cGVHD) incidence was 42% vs 27% (P < .01) and extensive cGVHD incidence was 9% vs 12% (P = .33) in TBI and CT cohorts, respectively. Graft failure was reported in two (2%) TBI- and 65 (7%) CT-MAC recipients (P = .08). Death from veno-occlusive disease was reported in one (3%) TBI and 11 (3%) CT patients who died during the study period. In the multivariate analysis, TBI was associated with increased risk for overall cGVHD (hazard ratio = 1.95, 95% confidence interval:1.2-3.1, P < .01) compared to CT-based MAC. The choice of conditioning regimen did not impact relapse incidence, leukemia-free survival, non-relapse mortality, overall survival or GVHD-relapse-free survival in multivariate analysis. In conclusion, major transplant outcomes were not statistically different between TBI-based MAC and CT-based MAC in patients with AML after haplo-HCT/PTCy.
PMID: 32656791
ISSN: 1096-8652
CID: 4600752